Key terms

About EDIT

Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. Its technology includes clustered, regularly interspaced short palindromic repeats (CRISPR), and CRISPR associated protein 9 (Cas9). The company was founded by Feng Zhang, Jennifer A. Doudna, George McDonald Church, J. Keith Joung and David R. Liu in September 2013 and is headquartered in Cambridge, MA.

Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
     
52-week range
     
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date

Key terms

Smart score

Latest EDIT news

Mar 05 7:25am ET Editas Medicine (EDIT) Receives a New Rating from a Top Analyst by TipRanks Mar 01 1:17am ET Strong Buy Rating for Editas Medicine: Promising Pipeline and Strategic IP Position Drive Optimism by TipRanks Mar 01 1:06am ET Editas Medicine: Balanced Prospects and a Hold Rating with Modest Price Target Increase by TipRanks Feb 29 8:07am ET Oppenheimer Sticks to Its Hold Rating for Editas Medicine (EDIT) by TipRanks Feb 29 7:19am ET RBC Capital Reaffirms Their Hold Rating on Editas Medicine (EDIT) by TipRanks Feb 29 6:28am ET Editas Medicine price target raised to $16 from $11 at Citi by TipRanks Feb 29 5:45am ET Editas Medicine price target raised to $11 from $10 at Barclays by TipRanks Feb 29 5:43am ET Hold Rating on Editas Medicine Pending Clinical Trial Outcomes and Market Differentiation Potential by TipRanks Feb 29 5:41am ET Buy Recommendation for Editas Medicine Backed by Strong SCD Treatment Outlook and Solid Financials by TipRanks Feb 29 2:51am ET Analysts’ Opinions Are Mixed on These Healthcare Stocks: Schrodinger (SDGR), Editas Medicine (EDIT) and MacroGenics (MGNX) by TipRanks Feb 28 5:28pm ET Editas Medicine files automatic mixed securities shelf by TipRanks Feb 28 12:15pm ET TD Cowen Sticks to Its Buy Rating for Editas Medicine (EDIT) by TipRanks Feb 28 7:03am ET Editas Medicine expects cash to fund operations into 2026 by TipRanks Feb 28 7:02am ET Editas Medicine reports Q4 EPS (23c), consensus (54c) by TipRanks Jan 12 5:51am ET Optimistic Outlook for Editas Medicine Driven by Therapeutic Development and Regulatory Advancements by TipRanks Jan 09 5:17am ET Buy Rating for Editas Medicine Backed by Strong SCD Program and Promising Clinical Developments by TipRanks Jan 08 8:41am ET Editas Medicine highlights 2024 anticipated milestones, strategic priorities by TipRanks Jan 05 8:47pm ET RBC Capital Keeps Their Hold Rating on Editas Medicine (EDIT) by TipRanks Dec 14 8:22am ET Editas Medicine price target raised by $7 at Evercore ISI, here’s why by TipRanks Dec 13 11:55am ET Buy Rating Affirmed for Editas Medicine Amid Strategic Partnerships and Promising Treatment Data by TipRanks Dec 13 9:02am ET Editas Medicine, Vertex Pharmaceuticals enter license agreement for Cas9 by TipRanks Dec 13 7:40am ET Analysts Have Conflicting Sentiments on These Healthcare Companies: Centene (CNC), ESSA Pharma (EPIX) and Editas Medicine (EDIT) by TipRanks Dec 12 9:29am ET Editas Medicine price target raised by $5 at Truist, here’s why by TipRanks Dec 12 7:40am ET Wall Street Analysts Are Bullish on Top Healthcare Picks by TipRanks Dec 12 7:30am ET Analysts Offer Insights on Healthcare Companies: Inotiv (NOTV), Incyte (INCY) and Editas Medicine (EDIT) by TipRanks Dec 11 12:45pm ET Editas Medicine to hold a pharmaceutical update conference call by TipRanks Dec 11 12:02pm ET Editas presents new EDIT-301 safety and efficacy data in 17 patients by TipRanks Dec 11 4:55am ET Editas Medicine to hold a pharmaceutical update conference call by TipRanks

No recent press releases are available for EDIT

EDIT Financials

1-year income & revenue

Key terms

EDIT Forecasts

analyst rating

  • buy
  • hold
  • sell

We're sorry, but this
information is
temporarily unavailable.

1-year stock price forecast

EDIT Competitors

$ Market cap P/E ratio $ Price 1d change 52-week range

Key terms

Latest investing news

Trump Media, which runs the social media platform Truth Social, took the place of Digital World's place on the Nasdaq stock exchange in March.
Frank Franklin II/AP
Trump Media stock ends session 15% higher after two very bad days
Students at Highlands High School, work on a practice test at the ACT Boot Camp in Newport, Ky.
Patrick Reddy/The Enquirer/AP/File
Private equity finds its next bet: college admissions
In this photo illustration, Republican presidential candidate former President Donald Trump's social media platform Truth Social is shown on a cell phone on March 25, 2024 in Chicago, Illinois.
Scott Olson/Getty Images
Trump’s stock tumbles again after Truth Social announces it’s getting into streaming
Tim Wren, chief commercial officer for BSI Group, right, presents Kristalina Georgieva, chief executive officer of the World Bank Group, second right, with ISO 20121 certification for sustainable event management at an event during the spring meetings of the International Monetary Fund (IMF) and World Bank in Washington, DC, US, on Monday, April 15, 2024. The IMF and World Bank spring meetings in Washington are expected to draw thousands of delegates, observers and journalists from the fund's 190 member countries. Photographer: Samuel Corum/Bloomberg via Getty Images
Samuel Corum/Bloomberg/Getty Images
Geopolitical strife is roiling Wall Street. Here’s what investors are watching